

- Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. *Int J Cancer* 2003;105:546–551.
- Chang C-C, Chang Y-L, Lee Y-C. Thymic carcinoma associated with Sjogren's syndrome and syndrome of inappropriate antidiuretic hormone. *J Thorac Cardiovasc Surg* 2010;139(2):e1–e2.
- Kadowaki T, Hamada H, Yokoyama A, et al. Thymic carcinoma originating from the mid-posterior mediastinum. *Respirology* 2005;10:689–691.
- Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. *Cancer* 1991;67:1025–1032.
- Tomaszek S, Wigle DA, Keshavjee S, et al. Thymomas: review of current clinical practice. *Ann Thorac Surg* 2009;87:1973–1980.
- Shimizu K, Yoshida J, Kakegawa S, et al. Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. *J Thorac Oncol* 2010;5:117–121.
- Skandalakis JE, Gray SW, Todd NW. Pharynx and its derivatives. In: Skandalakis JE, Gray SW, eds. *Embryology for Surgeons*, 2nd ed. Baltimore: Williams & Wilkins; 1994.
- Von Gaudecker B. Functional histology of the human thymus. *Anat Embryol* 1991;183:1–15.
- Fukai I, Funato Y, Mizuno T, et al. Distribution of thymic tissue in the mediastinal adipose tissue. *J Thorac Cardiovasc Surg* 1991;101:1099–1102.
- Kazemi S, Kress DC, Cal RA, et al. A rare case of intracardiac thymoma. *Echocardiography* 2006;24:348–349.
- Tumors of the thymus pathology. In: Hartmann WH (ed) *Atlas of Tumor Pathology, Fascicle 13, Series 2*. Washington, DC: Armed Forces Institute of Pathology; 1976:34–153.
- Marino M, Muller-Hermelink HK. Thymoma and thymic carcinoma: relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. *Virchows Arch A Pathol Anat Histopathol* 1985;407:119–149.
- Kirchner T, Muller-Hermelink H. New approaches to the diagnosis of thymic epithelial tumors. *Prog Surg Pathol* 1989;10:167–189.
- Quintanilla-Martinez L, Wilkins EW, Choi N, et al. Thymoma: histologic subclassification is an important prognostic factor. *Cancer* 1994;74:606–617.
- Shimosato Y. Controversies surrounding the subclassification of thymoma. *Cancer* 1994;74:542–544.
- Suster S, Moran CA. Primary thymic epithelial neoplasms: current concepts and controversies. In: Fechner RE, Rosen PP, eds. *Anatomic Pathology 1997, Vol 2*. Chicago: American Society for Clinical Pathology Press; 1997: 1.
- Marx A, Muller-Hermelink HK. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. *Pathol Res Pract* 1999; 195:515–533.
- Rieker RJ, Hoegel J, Morresi-Hauf A, et al. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. *Int J Cancer* 2002;98:900–906.
- Detterbeck FC. Clinical value of the WHO classification system of thymoma. *Ann Thorac Surg* 2006;81:2328–2334.
- Suster S, Moran CA. Thymoma classification: current status and future trends. *Am J Clin Pathol* 2006;125:542–554.
- Patterson GA. Thymomas. *Semin Thorac Cardiovasc Surg* 1992;4:39–44.
- Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. *Cancer* 1981;48:2485–2492.
- Okumura M, Ohta M, Tateyama H, et al. The World Health Organization Histologic Classification System reflects oncologic behavior of thymoma. *Cancer* 2002;94:624–632.
- Gamondes JP, Balawi A, Greenland T, et al. Seventeen years of surgical treatment of thymoma: factors influencing survival. *Eur J Cardiothorac Surg* 1991;5:124–131.
- Bedini AV, Andreani SM, Tavecchio L, et al. Proposal of a novel system for the staging of thymic epithelial tumors. *Ann Thorac Surg* 2005;80: 1994–2000.
- Hsu CP, Chan CY, Chen CL, et al. Thymic carcinoma: ten years' experience in twenty patients. *J Thorac Cardiovasc Surg* 1994;107:615–620.
- Shimizu J, Hayashi Y, Monita K, et al. Primary thymic carcinoma: a clinicopathological and immunohistochemical study. *J Surg Oncol* 1994;56: 159–164.
- Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. *Hum Pathol* 1978;9:495–515.
- Weide LG, Ulbright TM, Loehrer PJ, et al. Thymic carcinoma: a distinct clinical entity responsive to chemotherapy. *Cancer* 1993;71:1219–1223.
- Suster S, Moran CA. Spindle cell thymic carcinoma: clinicopathologic and immunohistochemical study of a distinctive variant of primary thymic epithelial neoplasm. *Am J Surg Pathol* 1999;23:681–700.
- Marchevsky AM, Gupta R, McKenna RJ, et al. Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. *Cancer* 2008;112:2780–2788.
- Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clin Cancer Res* 2009;15:6790–6799.
- Davis RD, Oldham HN, Sabiston DC. The mediastinum. In: Sabiston DC, Spencer FC, eds. *Surgery of the Chest*. 5th ed. Philadelphia: WB Saunders; 1989.
- Iwata T, Inoue K, Mizuguchi S, et al. Thymectomy for paraneoplastic stiff-person syndrome associated with invasive thymoma. *J Thorac Cardiovasc Surg* 2006;132:196–197.
- Rinadi TP, Batocchi AP, Evoli A, et al. Thymic lesions and myasthenia gravis: diagnosis based on mediastinal imaging and pathological findings. *Acta Radiol* 2002;43:380–384.
- Hengstman GJ, Drost G, Wagenaar M, et al. Persistent increased risk for thymoma in myasthenia gravis associated with myositis. *Muscle Nerve* 2006; 34:251–252.
- Berrih-Akin S, Morel E, Raimond F, et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. *Ann N Y Acad Sci* 1987;505:50–71.
- Ströbel P, Preishofen T, Helmreich M, et al. Pathomechanisms of paraneoplastic myasthenia gravis. *Clin Dev Immunol* 2003;10:7–12.
- Blossom GB, Ernstoff RM, Howells GA, et al. Thymectomy for myasthenia gravis. *Arch Surg* 1993;128:854–862.
- Lopez-Cano M, Ponseti-Bosch JM, Espin-Basany E, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. *Ann Thorac Surg* 2003;76:1643–1649.
- Okereke IC, Kesler KA, Morad MH, et al. Prognostic indicators after surgery for thymoma. *Ann Thorac Surg* 2010;89:1071–1077.
- Palmieri C, Lastoria S, Cala O, et al. Successful treatment of a patient with a thymoma and pure red cell aplasia with octreotide and prednisone. *N Engl J Med* 1997;336:263–265.
- Zauchar R, Zaucha JM, Jassem J. Resolution of thymoma-related pure red cell aplasia after octreotide. *Acta Oncologica* 2007;46:864–865.
- Kelesidis T, Yang O. Good's syndrome remains a mystery after 54 years. A systematic review of the scientific evidence. *Clin Immunol* 2010;135: 347–363.
- Nasseri F, Eftekhari F. Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls. *Radiographics* 2010;30:413–428.
- Bogot NR, Quint LE. Imaging of thymic disorders. *Cancer Imaging* 2005; 5:139–149.
- Tomiyama H, Muller NL, Ellis SJ, et al. Invasive and noninvasive thymoma: distinctive CT features. *J Comput Assist Tomogr* 2001;25:388–393.
- Inoue A, Tomiyama N, Fujimoto K, et al. MR imaging of thymic epithelial tumors: correlation with World Health Organization classification. *Radiat Med* 2006;24:171–181.
- Benveniste MF, Moran CA, Mawlawi O, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. *J Thorac Oncol* 2013;8:502–510.
- Lococo F, Cesario A, Okami J, et al. Role of combined (18)F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: A multicenter analysis. *Lung Cancer* 2013;82:245–251.
- Thomas A, Mena E, Kurdziel K, et al. 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. *Clin Cancer Res* 2013;19:1487–1493.
- Morrissey B, Adams H, Gibbs AR, et al. Percutaneous needle biopsy of the mediastinum: review of 94 procedures. *Thorax* 1993;48:632–637.
- Bressler EL, Kirkham JA. Mediastinal masses: alternative approaches to CT-guided needle biopsy. *Radiology* 1994;191:391–396.
- Redina EA, Venuta F, DeGiacomo T, et al. Comparative merits of thoracoscopy, mediastinoscopy, and mediastinotomy for mediastinal biopsy. *Ann Thorac Surg* 1994;57:992–995.
- Redina EA, Venuta F, DeGiacomo T, et al. Biopsy of anterior mediastinal masses under local anesthesia. *Ann Thorac Surg* 2002;74:1720–1722.
- Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. *J Thorac Oncol* 2009;4:911–919.
- Detterbeck F, Giaccone G, Loehrer P, et al. International thymic malignancy interest group. *J Thorac Oncol* 2010;5:1–2.
- Maggi G, Casadio C, Cavallo A, et al. Thymoma: results of 241 operated cases. *Ann Thorac Surg* 1991;51:152–156.
- Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. *Ann Thorac Surg* 2003;76:878–884.
- Crucitti F, Daghetto GB, Bellantone R, et al. Effects of surgical treatment in thymoma with myasthenia gravis: our experience in 103 patients. *J Surg Oncol* 1992;50:43–46.
- Cowen D, Mormex RF, Bachelot T, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. *Radiation Oncol* 1995;34:9–16.
- Liu TJ, Lin MW, Hsieh MS, et al. Video-assisted thoracoscopic surgical thymectomy to treat early thymoma: a comparison with the conventional transsternal approach. *Ann Surg Oncol* 2004;21:322–328.
- Marulli G, Rea F, Melfi F, et al. Robot-aided thoracoscopic thymectomy for early-stage thymoma: a multicenter European study. *J Thorac Cardiovasc Surg* 2012;144:1125–1130.
- Weksler B, Tavares J, Newhook TE, et al. Robot-assisted thymectomy is superior to transsternal thymectomy. *Surg Endosc* 2012;26:261–266.
- Pollack A, Komaki R, Cox JD, et al. Thymoma: treatment and prognosis. *Int J Radiat Oncol Biol Phys* 1992;23:1037–1043.
- Latz D, Schraube P, Oppitz U, et al. Invasive thymoma: treatment with postoperative radiation therapy. *Radiology* 1997;204:859–864.

67. Ciernik IF, Meier U, Lutolf UM. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. *J Clin Oncol* 1994;12:1484-1490.
68. Zhu G, He S, Fu X, et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. *Int J Radiat Oncol Biol Phys* 2004;60:1113-1119.
69. Marks LB. The impact of organ structure on radiation response. *Int J Radiat Oncol Biol Phys* 1996;34:1165-1171.
70. Onuki T, Ishikawa S, Yamamoto T, et al. Pathologic radio response of preoperatively irradiated invasive thymomas. *J Thorac Oncol* 2008;3:270-276.
71. Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. *J Thorac Cardiovasc Surg* 2005;130:1413-1421.
72. D'Angelillo RM, Trodella L, Ramella S, et al. Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. *Int J Radiat Oncol Biol Phys* 2008;71:420-427.
73. Thomas CR Jr, Williams TE, Turrisi AT 3rd. Lung toxicity in the treatment of lung cancer: thoughts at the end of the millennium. In: Meyer J, Karger T, eds. *Radiation Injury: Prevention and Treatment. Frontiers of Radiation Therapy and Oncology*. Basel, Switzerland: Karger Medical and Scientific Publishers; 1999.
74. Kirschner PA. Reoperation for thymoma: report of 23 cases. *Ann Thorac Surg* 1990;49:550-554.
75. Bogart J, Sagerman RH. High-dose hemithorax irradiation in a patient with recurrent thymoma: a study of pulmonary and cardiac radiation tolerance. *Am J Clin Oncol* 1999;22:441-445.
76. Liu H-C, Chen Y-J, Tzen C-Y, et al. Debulking surgery for advanced Thymoma. *Eur J Surg Oncol* 2006;32:1000-1005.
77. Haniuda M, Miyazawa M, Yoshida K, et al. Is postoperative radiotherapy for thymoma effective? *Ann Surg* 1996;224:219-224.
78. Urgesi A, Monetti U, Rossi G, et al. Aggressive treatment of intrathoracic recurrences of thymoma. *Radiother Oncol* 1992;24:221-225.
79. Mornex F, Resbeut M, Richard P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. *Int J Radiat Oncol Biol Phys* 1995;32:651-659.
80. Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. *J Thorac Oncol* 2010;5:357-360.
81. Bonomi PD, Finkelstein D, Aisner S, et al. EST 2582 Phase II trial of cisplatin in metastatic or recurrent thymoma. *Am J Clin Oncol* 1993;16:342-345.
82. Kobayashi Y, Fujii Y, Yano M, et al. Preoperative steroid pulse therapy for invasive thymoma: clinical experience and mechanism of action. *Cancer* 2006;106:1901-1907.
83. Hammond-Thelin LA, Thomas CR Jr. Systemic therapeutic options in thymic malignancies: a glimmer of hope. *Rev Recent Clin Trials* 2007;2:191-205.
84. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. *J Clin Oncol* 2004;22:293-299.
85. Ionescu DN, Sasatomi E, Ciepely K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. *Cancer* 2005;103:630-636.
86. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. *N Engl J Med* 2004;350:2625-2626.
87. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. *J Pathol* 2004;202:375-381.
88. Lin J-T, Wei-Shu W, Yen C-C, et al. Stage IV thymic carcinoma: a study of 2-patients. *Am J Med Sci* 2005;330:172-175.
89. Magois E, Guigay J, Blancard PS, et al. Multimodal treatment of thymic carcinoma: report of nine cases. *Lung Cancer* 2008;59:126-132.
90. Loehrer PJ, Jirutek M, Aisner S, et al. Phase II trial of etoposide (V), ifosfamide (I), plus cisplatin (P) in patients with advanced thymoma (T) or thymic carcinoma (TC): preliminary results from a ECOG coordinated intergroup trial. *Proc Am Soc Clin Oncol* 1998;17:30 (abst 118).
91. Liu H, Hsu W, Chen Y, et al. Primary thymic carcinoma. *Ann Thorac Surg* 2002;73:1076-1081.
92. Yano T, Hara N, Ichinose Y, et al. Treatment and prognosis of primary thymic carcinoma. *J Surg Oncol* 1993;52:255-258.
93. Fornasiero A, Danilele O, Ghiotto C, et al. Chemotherapy for invasive thymoma: a 13 year experience. *Cancer* 1991;68:30-33.
94. Nieto IP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. *Ann Thorac Surg* 1999;67:1568-1571.
95. Fang W, Chen W, Chen G, et al. Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. *Ann Thorac Surg* 2005;80:2002-2007.
96. Kang M-W, Lee E-S, Jo J, et al. Stage III thymic epithelial neoplasms are not homogeneous with regard to clinical, pathological, and prognostic features. *J Thorac Oncol* 2009;4:1561-1567.
97. Quintanilla-Martinez L, Wilkins EW Jr, Ferry JA, et al. Thymoma: morphologic subclassification correlates with invasiveness and immunohistologic features. A study of 122 cases. *Hum Pathol* 1993;24:958-969.
98. Harris N. Classification of thymic epithelial neoplasms. In: Marx A, Muller-Hermelink HK, eds. *Epithelial Tumors of the Thymus. Pathology, Biology, Treatment*. New York: Plenum; 1997:1.
99. Mangi AA, Wain JC, Donahue DM, et al. Adjuvant radiation therapy of stage III thymoma: is it necessary? *Ann Thorac Surg* 2005;79:1834-1839.
100. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. *Cancer* 2009;115:5413-5420.
101. Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. *Ann Thorac Surg* 2009;87:1641-1647.
102. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. *Int J Radiat Oncol Biol Phys* 2010;76:440-445.
103. Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. *Int J Radiat Oncol Biol Phys* 2010;78:1400-1406.
104. Berman AT, Litzky L, Livolsi V, et al. Adjuvant radiotherapy for completely resected stage 2 thymoma. *Cancer* 2011;117:3502-3508.
105. Weksler B, Shende M, Nason KS, et al. The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study. *Ann Thorac Surg* 2012;93:1822-1828.
106. Harper P, Highly M, Rankin E, et al. Treatment of invasive thymoma with single-agent ifosfamide. *J Clin Oncol* 1999;17:2737-2744.
107. Tomiak EM, Evans WK. The role of chemotherapy in invasive thymoma: a review of the literature and considerations for future clinical trials. *Crit Rev Oncol Hematol* 1993;15:113-124.
108. Kirkove C, Berghmans J, Noel H, et al. Dramatic response of recurrent invasive thymoma to high dose corticosteroids. *Clin Oncol (R Coll Radiol)* 1992;4:64-66.
109. Loehrer PJ, Kim KM, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. *J Clin Oncol* 1994;12:1164-1168.
110. Park HS, Shin DM, Lee JS, et al. Thymoma: a retrospective study of 87 cases. *Cancer* 1994;73:2491.
111. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Lung Cancer Cooperative Group. *J Clin Oncol* 1996;14:814-820.
112. Lemma GL, Loehrer PJ, Lee JW, et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma and thymic carcinoma: EIC99. *J Clin Oncol* 2008;26:(abst 8018).
113. Tomiak EM, Evans WK. The role of chemotherapy in invasive thymoma: a review of the literature and considerations for future clinical trials. *Crit Rev Oncol Hematol* 1993;15:113-124.
114. Rea F, Sartori F, Lay M, et al. Chemotherapy and operation for invasive thymoma. *J Cardiovasc Surg* 1993;106:543-549.
115. Macchiarini P, Chella A, Ducci F, et al. Neoadjuvant chemotherapy, surgery and postoperative radiation therapy for invasive thymoma. *Cancer* 1991;68:706-713.
116. Kunitoh H, Tamura T, Shibata T, et al. A phase II trial of dose-dense chemotherapy followed by surgical resection and/or thoracic radiotherapy in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). *Br J Cancer* 2010;103:6-11.
117. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. *Ann Intern Med* 1998;129:100-104.
118. Papadopoulos KP, Thomas CR Jr. Current chemotherapy options for thymic epithelial neoplasms. *Expert Opin Pharmacother* 2005;6:1169-1177.
119. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clin Cancer Res* 2009;15:6790-6799.
120. Kelly RJ, Petrini I, Rajan A, et al. Thymic malignancies: from clinical management to targeted therapies. *J Clin Oncol* 2011;29:4820-4827.
121. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. *Jpn J Clin Oncol* 2006;36:351-356.
122. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. *Lancet Oncol* 2007;8:449-450.
123. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. *Front Biosci* 2007;12:757-761.
124. Giaccone G, Rajan A, Ruijter R, et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. *J Thorac Oncol* 2009;4:1270-1273.
125. Ströbel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. *Br J Cancer* 2010;103:196-200.
126. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. *J Clin Oncol* 2011;29:2052-2059.
127. Henley JD, Koukoulis GK, Loehrer PJ Sr. Epidermal growth factor receptor expression in invasive thymoma. *J Cancer Res Clin Oncol* 2002;128:167-170.
128. Kong D-S, Lee J-I, Nam DH, et al. Cerebral involvement of metastatic thymic carcinoma. *J Neurooncol* 2005;75:143-147.

129. Rosai J, Higa E. Mediastinal endocrine neoplasm of probable thymic origin related to carcinoid tumors. *Cancer* 1972;29:1061–1074.
130. Wang DY, Chang DB, Kuo SH, et al. Carcinoid tumors of the thymus. *Thorax* 1994;49:357–360.
131. Vietri F, Illuminati R, Guglielmi R, et al. Carcinoid tumor of the thymus gland. *Eur J Surg* 1994;160:645–647.
132. Gibril F, Chen YJ, Schrupp DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. *J Clin Endocrinol Metab* 2003;88:1066–1081.
133. Asbun HJ, Calabria RP, Calmes S, et al. Thymic carcinoid. *Am Surg* 1991; 57:442–445.
134. Zeiger MA, Swartz SE, Macgillivray DC, et al. Thymic carcinoid in association with MEN syndromes. *Am Surg* 1992;58:430–434.
135. Chaer R, Massad MC, Evans E, et al. Primary neuroendocrine tumors of the thymus. *Ann Thorac Surg* 2002;74:1733–1740.
136. Weissferdt A, Tang X, Wistuba II, et al. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. *Mod Pathol* 2013;26:1554–1560.
137. Tiffet O, Nicholson AG, Landas G, et al. A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. *Chest* 2003;124:141–146.
138. Ferolla P, Falchetti A, Filooso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. *J Clin Endocrinol Metab* 2005;90:2603–2609.
139. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. *Am J Clin Pathol* 2000;114:100–110.
140. McManus KG, Allen MS, Trastek VF, et al. Lipothymoma with red cell aplasia, hypogammaglobulinemia and lichen planus. *Ann Thorac Surg* 1994; 58:1534–1536.
141. Rosado-de-Christenson ML, Pugatch RD, Moran CA, et al. Thymolipoma: analysis of 27 cases. *Radiology* 1994;193:121–126.
142. Litano Y, Yokomari K, Ohkura M, et al. Giant thymolipoma in a child. *J Pediatr Surg* 1993;28:1622–1625.
143. Zambudio AR, Lanzas JT, Roca Calvo MJ, et al. Thymolipomas in association with myasthenia gravis. *J Thorac Cardiovasc Surg* 2001;122:825–826.
144. Kilic D, Giray S, Bolat FA, et al. A rare combination of thymic tumor: radiologically invisible thymolipoma associated with myasthenia gravis. *Neurol India* 2006;54:322–324.
145. Jiang X, Fang Y, Wang G. Images in cardiothoracic surgery. Giant thymolipoma involving both chest cavities. *Ann Thorac Surg* 2009;87:1960.
146. Nichols CR, Fox EP. Extragonadal and pediatric germ cell tumors. *Hematol Oncol Clin North Am* 1991;5:1189–1209.
147. Hainsworth JD, Greco FA. Extragonadal germ cell tumors and unrecognized germ cell tumors. *Semin Oncol* 1992;19:119–127.
148. Dulmet EM, Macchiarini P, Sue B, et al. Germ cell tumors of the mediastinum: a 30-year experience. *Cancer* 1993;72:1894–1901.
149. Luna M, Valenzuela-Tamaritz J. Germ-cell tumors of the mediastinum, post-mortem findings. *Am J Clin Pathol* 1976;65:450–454.
150. Lemarié E, Assouline PS, Diot P, et al. Primary mediastinal germ cell tumors. Results of a French retrospective study. *Chest* 1992;102: 1477–1483.
151. Wu TT, Wang HC, Chang YC, et al. Mature mediastinal teratoma: sonographic imaging patterns and pathologic correlation. *J Ultrasound Med* 2002; 21:759–765.
152. Ginsberg RJ. Mediastinal germ cell tumors: the role of surgery. *Semin Thorac Cardiovasc Surg* 1992;4:51–54.
153. Bokemeyer C, Nichols CR, Draz J, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. *J Clin Oncol* 2002;20:1864–1873.
154. Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. *Eur J Radiol* 2005;54:284–288.
155. Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. *J Clin Oncol* 2001;19: 1641–1648.
156. Nakamura Y, Matsumura A, et al. Cisplatin-based chemotherapy followed by surgery for malignant nonseminomatous germ cell tumor of mediastinum: one institution's experience. *Gen Thorac Cardiovasc Surg* 2009;57: 363–368.
157. Kesler KA, Einhorn LH. Multimodality treatment of germ cell tumors of the mediastinum. *Thorac Surg Clin* 2009;19:63–69.
158. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol* 1997;15:594–603.